EUVIMEDObjevte EUVIMED
Multizentrische Studie

Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real‐life clinical practice

E Muñoz-Aceituno, B Butrón-Bris iD, M C Ovejero-Benito iD, A Sahuquillo-Torralba iD, O Baniandrés Rodríguez, E Herrera-Acosta, R Rivera-Diaz iD, M Ferran, J L Sánchez-Carazo, J Riera-Monroig iD, J Pujol-Montcusí, D Vidal and 14 more

Journal of the European Academy of Dermatology and Venereology · 2024-09 · 38 (9) · 1783-1790

DOI: 10.1111/jdv.19782 ↗

At a glance

Multizentrische Studie in Journal of the European Academy of Dermatology and Venereology, published online on 2023-12-28. Written by E Muñoz-Aceituno and 25 co-authors. Institution: Department of Dermatology, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria La Princesa, Madrid, Spain. Major MEDLINE topics: Psoriasis, Antibodies, Monoclonal, Humanized, Polymorphism, Single Nucleotide. Cited 10 times so far (Crossref); 32 references. Funded by: Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional, Novartis.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Prediction of the response to a biological treatment in psoriasis patients would allow efficient treatment allocation.

Objective

To identify polymorphisms associated with secukinumab response in psoriasis patients in a daily practice setting.

Methods

We studied 180 SNPs in patients with moderate‐to‐severe plaque psoriasis recruited from 15 Spanish hospitals. Treatment effectiveness was evaluated by absolute PASI ≤3 and ≤1 at 6 and 12 months. Individuals were genotyped using a custom Taqman array. Multiple logistic regression models were generated. Sensitivity, specificity and area under the curve (AUC) were analysed.

Results

A total of 173 patients were studied at 6 months, (67% achieved absolute PASI ≤ 3 and 65% PASI ≤ 1) and 162 at 12 months (75% achieved absolute PASI ≤ 3 and 64% PASI ≤ 1). Multivariable analysis showed the association of different sets of SNPs with the response to secukinumab. The model of absolute PASI≤3 at 6 months showed best values of sensitivity and specificity. Four SNPs were associated with the capability of achieving absolute PASI ≤ 3 at 6 months. rs1801274 ( FCGR2A ), rs2431697 ( miR‐146a ) and rs10484554 ( HLCw6 ) were identified as risk factors for failure to achieve absolute PASI≤3, while rs1051738 ( PDE4A) was protective. AUC including these genotypes, weight of patients and history of biological therapy was 0.88 (95% CI 0.83–0.94), with a sensitivity of 48.6% and specificity of 95.7% to discriminate between both phenotypes.

Conclusion

We have identified a series of polymorphisms associated with the response to secukinumab capable of predicting the potential response/non‐response to this drug in patients with plaque psoriasis.

Subjects

MeSH terms (MEDLINE)

PsoriasisAntibodies, Monoclonal, HumanizedPolymorphism, Single NucleotideHumansFemaleMaleMiddle AgedAdultDermatologic AgentsMicroRNAsSeverity of Illness IndexTreatment Outcome

Substances

secukinumabAntibodies, Monoclonal, HumanizedMIRN146 microRNA, humanDermatologic AgentsMicroRNAs

Authors and institutions

  • Department of Dermatology, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria La Princesa, Madrid, Spain.
  • Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, CEU, CEU Universities Madrid, Madrid, Spain.
  • Department of Dermatology, Hospital Universitario y Politécnico La Fe, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.
  • Department of Dermatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Department of Dermatology, Hospital Virgen de la Victoria, Málaga, Spain.
  • Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain.

ORCID profiles: B Butrón-Bris, M C Ovejero-Benito, A Sahuquillo-Torralba, R Rivera-Diaz, J Riera-Monroig, P de la Cueva, R Ruiz-Villaverde, M Llamas-Velasco, E Daudén-Tello, H de la Fuente

Funding

  • Instituto de Salud Carlos III
  • Fondo Europeo de Desarrollo Regional
  • Novartis
  • European Regional Development Fund

Cite

APA

Muñoz-Aceituno, E., Butrón-Bris, B., Ovejero-Benito, M. C., Sahuquillo-Torralba, A., Baniandrés Rodríguez, O., Herrera-Acosta, E., Rivera-Diaz, R., Ferran, M., Sánchez-Carazo, J. L., Riera-Monroig, J., Pujol-Montcusí, J., Vidal, D., de la Cueva, P., García-Bustinduy, M., Ruiz-Villaverde, R., Ballescà, F., Llamas-Velasco, M., Navares, M., Palomar-Moreno, I., …, & de la Fuente, H. (2024). Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real‐life clinical practice. Journal of the European Academy of Dermatology and Venereology, 38(9), 1783-1790. https://doi.org/10.1111/jdv.19782

Vancouver

Muñoz-Aceituno E, Butrón-Bris B, Ovejero-Benito MC, Sahuquillo-Torralba A, Baniandrés Rodríguez O, Herrera-Acosta E, et al. Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real‐life clinical practice. Journal of the European Academy of Dermatology and Venereology. 2024;38(9):1783-1790. doi:10.1111/jdv.19782

BibTeX
@article{MuozAceituno2024,
  author = {Muñoz-Aceituno, E and Butrón-Bris, B and Ovejero-Benito, M C and Sahuquillo-Torralba, A and Baniandrés Rodríguez, O and Herrera-Acosta, E and Rivera-Diaz, R and Ferran, M and Sánchez-Carazo, J L and Riera-Monroig, J and Pujol-Montcusí, J and Vidal, D and de la Cueva, P and García-Bustinduy, M and Ruiz-Villaverde, R and Ballescà, F and Llamas-Velasco, M and Navares, M and Palomar-Moreno, I and Sánchez-García, I and García-Martínez, J and Novalbos, J and Zubiaur, P and Abad-Santos, F and Daudén-Tello, E and de la Fuente, H},
  title = {Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real‐life clinical practice},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2024},
  volume = {38},
  number = {9},
  pages = {1783--1790},
  doi = {10.1111/jdv.19782}
}
Start for free →